{"id":726060,"date":"2023-01-26T07:33:32","date_gmt":"2023-01-26T12:33:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-february-investor-conferences\/"},"modified":"2023-01-26T07:33:32","modified_gmt":"2023-01-26T12:33:32","slug":"agenus-to-participate-in-february-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-february-investor-conferences\/","title":{"rendered":"Agenus to Participate in February Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>LEXINGTON, Mass., Jan.  26, 2023  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=odpeaIk9IR3M2-NZyOqwulDA-S7_NnG6660vtL1TM9LP3upsUWHLHugIjS3bG72lfOvfkAzIk6BpH0clWvRR7XpsTXWOsDp8a9tGnQfbaoCrd_g3ecpaRcdBH58bvfAqXemwXul4oYKOyyQmZTqvEQ==\" rel=\"nofollow noopener\" target=\"_blank\">Agenus<\/a> (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO, and Dr. Steven O\u2019Day, Chief Medical Officer, will participate in the following upcoming investor conferences:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">\n          <strong>Guggenheim 5<\/strong><br \/>\n          <sup><br \/>\n            <strong>th<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual Oncology Day <\/strong>\u2013 Fireside chat presentation will be held in-person on Thursday, February 9th, 2023 at 9:35 AM ET<\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>SVB Securities Global Biopharma Conference<\/strong> \u2013 Fireside chat presentation will be held virtually on Thursday, February 16th, 2023 at 10:00 AM ET<\/li>\n<\/ul>\n<p>A live webcast of the presentations from Guggenheim and SVB Securities conferences can be accessed on the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ONW_CcAlBCMs9nLFO5hLYq8v7hTuy2I37urDSv2DOkZ4GaufFWw8qknoprZ21HBMvipSMJu78wS3aBJmULGaxsN-lza_yUaV5hzSc9MB-w9uuA8d7N_fcgwsK27oAoRpgqpeDdDBOG2BpCmiDBnucOPGLr8UwRjz-Ndy0JvhssUFpmCLbSA49gBZ5VkOiNzT\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/investor.agenusbio.com\/events-and-presentations<\/a>. A replay will be posted following the event.<\/p>\n<p>\n        <strong><br \/>\n          <u>About Agenus<br \/><\/u><br \/>\n        <\/strong>Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body&#8217;s immune system to fight cancer and infections. The Company&#8217;s vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.<\/p>\n<p>\n        <strong><br \/>\n          <u>Contact<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>Agenus Inc.<br \/>Zack Armen<br \/>Head of Investor Relations<br \/>917-362-1370<br \/>zack.armen@agenusbio.com<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNjc5NyM1Mzc1MjAwIzIwMjAwNDA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MTQyZmMwMmYtOTI0OS00ZTA4LWEwMGQtMzE3ZDFiN2NmZGM0LTEwMzE2MTI=\/tiny\/Agenus-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) &#8212; Agenus (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO, and Dr. Steven O\u2019Day, Chief Medical Officer, will participate in the following upcoming investor conferences: Guggenheim 5 th Annual Oncology Day \u2013 Fireside chat presentation will be held in-person on Thursday, February 9th, 2023 at 9:35 AM ET SVB Securities Global Biopharma Conference \u2013 Fireside chat presentation will be held virtually on Thursday, February 16th, 2023 at 10:00 AM ET A live webcast of the presentations from Guggenheim and SVB Securities conferences can be accessed on the company\u2019s website at https:\/\/investor.agenusbio.com\/events-and-presentations. A replay will be posted &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-february-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Agenus to Participate in February Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-726060","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Agenus to Participate in February Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-february-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Agenus to Participate in February Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) &#8212; Agenus (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO, and Dr. Steven O\u2019Day, Chief Medical Officer, will participate in the following upcoming investor conferences: Guggenheim 5 th Annual Oncology Day \u2013 Fireside chat presentation will be held in-person on Thursday, February 9th, 2023 at 9:35 AM ET SVB Securities Global Biopharma Conference \u2013 Fireside chat presentation will be held virtually on Thursday, February 16th, 2023 at 10:00 AM ET A live webcast of the presentations from Guggenheim and SVB Securities conferences can be accessed on the company\u2019s website at https:\/\/investor.agenusbio.com\/events-and-presentations. A replay will be posted &hellip; Continue reading &quot;Agenus to Participate in February Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-february-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-26T12:33:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNjc5NyM1Mzc1MjAwIzIwMjAwNDA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-february-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-february-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Agenus to Participate in February Investor Conferences\",\"datePublished\":\"2023-01-26T12:33:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-february-investor-conferences\\\/\"},\"wordCount\":267,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-february-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNjc5NyM1Mzc1MjAwIzIwMjAwNDA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-february-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-february-investor-conferences\\\/\",\"name\":\"Agenus to Participate in February Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-february-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-february-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNjc5NyM1Mzc1MjAwIzIwMjAwNDA=\",\"datePublished\":\"2023-01-26T12:33:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-february-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-february-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-february-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNjc5NyM1Mzc1MjAwIzIwMjAwNDA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNjc5NyM1Mzc1MjAwIzIwMjAwNDA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-february-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Agenus to Participate in February Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Agenus to Participate in February Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-february-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Agenus to Participate in February Investor Conferences - Market Newsdesk","og_description":"LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) &#8212; Agenus (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO, and Dr. Steven O\u2019Day, Chief Medical Officer, will participate in the following upcoming investor conferences: Guggenheim 5 th Annual Oncology Day \u2013 Fireside chat presentation will be held in-person on Thursday, February 9th, 2023 at 9:35 AM ET SVB Securities Global Biopharma Conference \u2013 Fireside chat presentation will be held virtually on Thursday, February 16th, 2023 at 10:00 AM ET A live webcast of the presentations from Guggenheim and SVB Securities conferences can be accessed on the company\u2019s website at https:\/\/investor.agenusbio.com\/events-and-presentations. A replay will be posted &hellip; Continue reading \"Agenus to Participate in February Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-february-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2023-01-26T12:33:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNjc5NyM1Mzc1MjAwIzIwMjAwNDA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-february-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-february-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Agenus to Participate in February Investor Conferences","datePublished":"2023-01-26T12:33:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-february-investor-conferences\/"},"wordCount":267,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-february-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNjc5NyM1Mzc1MjAwIzIwMjAwNDA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-february-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-february-investor-conferences\/","name":"Agenus to Participate in February Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-february-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-february-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNjc5NyM1Mzc1MjAwIzIwMjAwNDA=","datePublished":"2023-01-26T12:33:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-february-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-february-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-february-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNjc5NyM1Mzc1MjAwIzIwMjAwNDA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNjc5NyM1Mzc1MjAwIzIwMjAwNDA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-february-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Agenus to Participate in February Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/726060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=726060"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/726060\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=726060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=726060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=726060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}